THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Tuesday, November 26, 2019
Pharmaceutical manufacturers are experiencing a move toward lower volumes, faster product runs, higher product mixes, and increased digitization. There are more technologies and tools available now to help manufacturers grow and improve patient outcomes.
FREMONT, CA: Pharmaceutical companies are experiencing a period of rapid innovation. Pharma manufacturers are finding new, innovative, and creative ways to create value in highly regulated contexts. Below given are the digital technologies, processes, and products which define the drug production landscape in the coming years.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Personalized Medicine
Personalized medicine, which is also called precision medicine, is a method of diagnosing and tailoring therapies to patients based on their predicted response to the treatment. The emergence of personalization has various impacts on the manufacturers, as personalized medicines are small, and may need multiple treatment variations.
Digitization of Paper Processes
Innovative technologies like artificial intelligence, AR, and IIoT might steal the headlines, many manufacturers realizing significant benefits by beginning their digitization with paper processes. Manufacturers can institute electronic logbooks and digital batch records, to enhance the visibility and competence with little upfront investment. By replacing paper-based processes with digital ones, producers can make compliance an easy part of the process, eradicate the data loss and transcription errors, and enhance operational efficiency.
See Also: APAC CIO Outlook
Cloud
With improvements in security and cost, the pharmaceutical producers are adopting cloud computing and storage in force. Cloud infrastructure is an essential and first step toward widening the IIoT capabilities, and it makes sure that the data integrity and sharing across a product's lifecycle simpler. Particularly, the growth of PaaS has provided the pharmaceutical manufacturers with the opportunity to build and configure while ensuring all development is contained in a firmly controlled ecosystem.
Low Volume Production
Personalization is not only the trend that is contributing to the expansion of low-volume production in drug manufacturing. It reflects an industry-wide shift from low-cost drugs applicable to a large population to high-value, targeted therapies. The low-volume production will help attain life-saving drugs to the patients. This can make it difficult in the manufacturing process. On the other hand, low volume production helps to produce therapies for smaller patient populations. Besides linking the sophisticated overviews and production procedures, low-volume drugs face the same good manufacturing practice validation process as high-volume drugs.
Check This Out: Top Medical Device Manufacturing Companies in APAC
Check Out: The Manufacturing Outlook
More in News